These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20181461)

  • 21. Symptomatic remission and cognitive impairment in first-episode schizophrenia: a prospective 3-year follow-up study.
    Chang WC; Ming Hui CL; Yan Wong GH; Wa Chan SK; Ming Lee EH; Hai Chen EY
    J Clin Psychiatry; 2013 Nov; 74(11):e1046-53. PubMed ID: 24330905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response.
    Jäger M; Riedel M; Schmauss M; Pfeiffer H; Laux G; Naber D; Gaebel W; Huff W; Schmidt LG; Heuser I; Buchkremer G; Kühn KU; Rüther E; Hoff P; Gastpar M; Bottlender R; Strauss A; Möller HJ
    Psychiatry Res; 2008 Apr; 158(3):297-305. PubMed ID: 18280582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
    Olié JP; Spina E; Murray S; Yang R
    Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early improvement in PANSS-30, PANSS-8, and PANSS-6 scores predicts ultimate response and remission during acute treatment of schizophrenia.
    Lin CH; Lin HS; Lin SC; Kuo CC; Wang FC; Huang YH
    Acta Psychiatr Scand; 2018 Feb; 137(2):98-108. PubMed ID: 29280500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An early improvement in depressive symptoms predicts symptomatic remission of schizophrenia treated with quetiapine: a multicenter, 4-week case-control study.
    Chou YH; Chiu NM; Yang TT; Feng J; Chan CC; Lee HK;
    Int Clin Psychopharmacol; 2013 Sep; 28(5):255-60. PubMed ID: 23820333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection.
    Lasser RA; Bossie CA; Gharabawi GM; Kane JM
    Schizophr Res; 2005 Sep; 77(2-3):215-27. PubMed ID: 15908183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?
    Schennach-Wolff R; Jäger M; Obermeier M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Kühn KU; Lemke MR; Rüther E; Klingberg S; Gastpar M; Seemüller F; Möller HJ; Riedel M
    World J Biol Psychiatry; 2010 Aug; 11(5):729-38. PubMed ID: 20380620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response trajectories in "real-world" naturalistically treated schizophrenia patients.
    Schennach R; Meyer S; Seemüller F; Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Musil R; Möller HJ; Riedel M
    Schizophr Res; 2012 Aug; 139(1-3):218-24. PubMed ID: 22658528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Remission in schizophrenia: analysis in a naturalistic setting.
    Eberhard J; Levander S; Lindström E
    Compr Psychiatry; 2009; 50(3):200-8. PubMed ID: 19374962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation.
    Chan HY; Lin AS; Chen KP; Cheng JS; Chen YY; Tsai CJ
    J Clin Psychopharmacol; 2013 Dec; 33(6):747-52. PubMed ID: 24100785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders.
    Schimmelmann BG; Mehler-Wex C; Lambert M; Schulze-zur-Wiesch C; Koch E; Flechtner HH; Gierow B; Maier J; Meyer E; Schulte-Markwort M
    J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):768-78. PubMed ID: 18315449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
    Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
    Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment adherence and insight in schizophrenia.
    Bitter I; Fehér L; Tényi T; Czobor P
    Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of acute schizophrenia with paliperidone ER: predictors for treatment response and benzodiazepine use.
    Heres S; Don L; Herceg M; Bidzan L; Blanc M; Siracusano A; Maciulis V; Lahaye M; Schreiner A
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():207-12. PubMed ID: 24096139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials.
    Kinon BJ; Ascher-Svanum H; Adams DH; Chen L
    J Clin Psychopharmacol; 2008 Oct; 28(5):544-9. PubMed ID: 18794651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Ratner Y; Gibel A; Yorkov V; Ritsner MS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia.
    Docherty JP; Baker RA; Eudicone J; Mathew S; Marcus RN; McQuade RD; Mankoski R
    Schizophr Res; 2010 Jul; 120(1-3):199-203. PubMed ID: 20547037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
    Lerner V; Miodownik C; Gibel A; Sirota P; Bush I; Elliot H; Benatov R; Ritsner MS
    J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
    Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
    Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.